We use first and third-party cookies to offer our services and collect statistical data. If you continue browsing this website you accept their use. More information Accept


Lesvi's product portfolio comprises CNS pharmaceuticals and nutraceuticals, unique dosage forms and products in other therapeutic areas such as antiemetic, anti-infective, cardiovascular, diseases and pain. 
Product Indication Dosage form Strength
Otilonium bromide Irritable bowel syndrome Film-coated tablets 40 mg
Paracetamol / Tramadol Analgesic Effervescent tablets 325/37.5 mg
Partnena® Rational combination for the prophylaxis of migraine, the nociceptive modulation and the reduction of tension states Jan 2014
Pipamperone Sleep disorders and psychomotor Tablets 40 and 120 mg
Pipamperone Sleep disorders and psychomotor Oral solution 20mg/ 5 ml
Piracetam Alzheimer Film-coated tablets 800 & 1200 mg
Piracetam Alzheimer Oral solution 333 mg/ml
Piracetam Alzheimer Solution for injection 200mg/ ml
Pramipexol Parkinson's IR tablets 0.088, 0.18, 0.35, 0.7 and 1.1 mg
Prasugrel Base Prophylaxis and therapy of thrombosis Film-coated tablets 5 and 10 mg
Pregabaline * Neuropathic pain Tablets 25, 50, 75, 100, 150, 200, 225 and 300 mg
Promethazine Agitation and restlessness Injection 25mg/ ml
Promethazine Agitation and restlessness Oral solution 20mg/ ml
100mg/ ml
Pyridostigmine Myasthenia gravis Film-coated tablets 60 mg
Pyridostigminie Myasthenia gravis XR tablets 180 mg
Quetiapine * Psychosis, schizophrenia, bipolar disoder Film-coated tablets 25, 50, 100, 150, 200, 300 and 400 mg
Quetiapine * Psychosis, schizophrenia, bipolar disoder Orodispersable tablets 25 and 50 mg
Quetidia® Useful for the management of anxiety disorders Sep 2014
Quetidia® oral solution Useful for the management of anxiety disorders Sep 2017
Rasagiline (tartrate) Parkinson's Tablets 1 mg

[*] Differentiated product
[**] Opioid

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.

© Neuraxpharm / LESVI. All rights reserved.